Adaptive Phage Therapeutics

Bethesda, United States

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.

Jun 2023

Series B

Biotechnology Health Care Pharmaceutical Therapeutics

Top Investors

Mayo ClinicAlexandria Venture InvestmentsDeerfieldU.S. Department of WarDeerfield Capital Management

Founder Contacts

19,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Adaptive Phage Therapeutics

Who are Adaptive Phage Therapeutics's investors?

Adaptive Phage Therapeutics's investors include Mayo Clinic, Alexandria Venture Investments, Deerfield, U.S. Department of War, Deerfield Capital Management.

Where is Adaptive Phage Therapeutics headquartered?

Adaptive Phage Therapeutics is headquartered in Bethesda, United States.

What does Adaptive Phage Therapeutics do?

Adaptive Phage Therapeutics provides therapeutic services intended to treat multi-drug resistant pathogenic bacteria.

What stage is Adaptive Phage Therapeutics at?

Adaptive Phage Therapeutics is at the Series B stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated June 9, 2023.

MLA

"Adaptive Phage Therapeutics — Funding & Investors." VCBacked, June 9, 2023, https://www.vcbacked.co/company/adaptive-phage-therapeutics. Accessed July 1, 2026.

APA

VCBacked. (2023). Adaptive Phage Therapeutics — Funding & Investors. Retrieved July 1, 2026, from https://www.vcbacked.co/company/adaptive-phage-therapeutics

Wikipedia (cite web)

{{cite web |title=Adaptive Phage Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/adaptive-phage-therapeutics |website=VCBacked |access-date=July 1, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated June 9, 2023.